Close
Close
Treatment News

Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjogren's Syndrome

3.0
3.0 from 5 votes
Wednesday, May 23, 2018

Learn more about:

Clinical Trials

HOD HASHARON, Israel - Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, announced that at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting on May 2, 2018 in Honolulu, Hawaii, new data was reported on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute.

The poster presentation titled, "The anti-inflammatory effect of isotonic glycerol in Sjogren's syndrome-related dry eye" was delivered by Dr. Huba J. Kiss and presented findings from a study conducted by him at the Department of Ophthalmology, Semmelweis University, in Budapest, Hungary.

"Based on this study, data shows that using LO2A resulted in a significant improvement of the subjective and objective symptoms of the Sjogren's syndrome-related dry eye disease. This data supports our development efforts for LO2A in multiple markets including Israel where we are currently enrolling patients in a randomized, double-masked Phase IV study in this indication. LO2A is already approved in the Netherlands for this indication," stated Wize's Chairman, Ron Mayron.

LO2A resulted in a significant improvement of the subjective and objective symptoms of Sjogren's syndrome-related dry eye disease in this study and importantly LO2A did so without the need for anti-inflammatory agents. Based on in vitro experiments, isotonic glycerol-induced decrease of HLA-DR expression may be responsible for this favourable effect.

The data showed that a three-month long use of LO2A resulted in a decrease of the lid parallel conjunctival folds (LIPCOF) degree from the initial 2.48±0.75 on the right eye and 2.57±0.75 on the left eye to 1.33±0.73 and 1.38±0.67, respectively. P values for both the right and left eye were <0.001. Initial lissamine green staining of the eye surface also decreased significantly, with a P value of 0.001 for both the right and left eye from 1.76±0.89 and 1.95±0.86 to 0.29±0.56 and 0.29±0.56, respectively. There was a significant decrease, with a P value of <0.001, in the ocular surface disease index (OSDI) values from 55.81±15.19 to 32.54±19.51. Tear secretion did not change significantly, with a P value of 0.38 for the right eye and a P value of 0.45 for the left. 21 patients were enrolled in this prospective, unmasked, self-controlled study.

About Dry Eye Syndrome (DES) and Sjogren's
Dry Eye Syndrome (DES) is caused by the reduced production and/or improper quality of tear film. One of the causes of reduced tear production is Sjögren's, a chronic autoimmune disease that is estimated to affect up to 4 million people in the U.S. In patients with DES and Sjogren's, the absence of adequate tear production disrupts the normal function of the tear film in protecting the surface of the eye, resulting in increased friction that damages the integrity of the corneal and conjunctival surface

About Wize
Wize Pharma, Inc. is a clinical-stage biopharmaceutical company currently focused on the treatment of ophthalmic disorders, including DES. Wize has in-licensed certain rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's syndrome in the United States, Israel, Ukraine, China and have an option to purchase the rights to additional territories. Wize is currently conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study of LO2A for patients with Sjögren's.

LO2A is currently registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH and in the Netherlands for the treatment of DES and Sjögren's. Wize's strategy involves engaging local or multinational distributors to handle the distribution of LO2A.

Contacts:
Noam Danenberg
Chief Operating Officer
+972-72-260-0536
noam@wizepharma.com

Source: Wize Pharma, Inc.
3.0
3.0 from 5 votes
Free Newsletter
Trending News
Related Videos
by Abidemi Uruejoma
410 views